Uses of hypoxia-inducible factor inhibitors
US9623070B2 · kind B2 · utility
0Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 11, 2016 |
| Grant date | Apr 18, 2017 |
| Priority date | — |
| Expiry date | Aug 11, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.